Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918

This article has now been updated. Please use the final version.

Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
Akihiro ShimizuIzumi ShiraiKyohei OgawaAkane MiuraKotaro HaruharaKentaro OshiroAkihiko HamaguchiShinya YokoteMasahiro OkabeHiroyuki UedaNobuo TsuboiMasato IkedaTakashi Yokoo
Author information
JOURNAL OPEN ACCESS Advance online publication

Article ID: 0241-22

Details
Abstract

Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (>7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal-change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.

Content from these authors
© 2022 by The Japanese Society of Internal Medicine
feedback
Top